The Grapefruit Warning and CBD
CBD inhibits liver enzymes, raising drug levels similarly to grapefruit juice.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
CBD is not inert. In your liver, it blocks the same enzyme machinery that breaks down roughly half of all prescription drugs—the same machinery grapefruit blocks. If your medication warns against grapefruit, that's a signal to talk to your pharmacist before adding CBD. The risk is real but manageable; most people on most drugs are fine. High-stakes drugs like warfarin or tacrolimus need monitoring. Low-dose CBD on unrelated medications? Probably fine. The key: don't assume it's safe just because it's natural or because you feel okay.
Plain-language summary
Grapefruit juice carries a warning on many prescription drugs because compounds in it (furanocoumarins) block CYP3A4, a liver enzyme that breaks down roughly half of all medications. When the enzyme is blocked, the drug builds up in your blood — sometimes to toxic levels.
CBD does something similar. In lab studies and in humans, CBD inhibits CYP3A4, CYP2C9, CYP2C19, and several other CYP and UGT enzymes Strong evidence[1][2]. That means CBD can raise blood levels of drugs metabolized by those enzymes, just as grapefruit does.
The practical shortcut: if your medication bottle says "avoid grapefruit," treat CBD with the same caution. It is not a perfect overlap — CBD and grapefruit hit different enzyme combinations — but it is a useful first filter.
This article is about interactions you need to know. It is not about whether CBD works for any condition; for that, see Cannabis and Polypharmacy Risks.
What probably works (well-established interactions)
These are interactions with strong human evidence, mostly from controlled trials or case series in real patients.
Clobazam (Onfi) — CBD substantially raises levels of N-desmethylclobazam, the active metabolite of clobazam. This was documented in pediatric epilepsy trials at doses around 20 mg/kg/day; many children needed clobazam dose reductions Strong evidence[3][4].
Warfarin — Case reports and case series show INR (the blood-clotting measure) increases when CBD is added. CBD inhibits CYP2C9, which metabolizes the more potent S-warfarin enantiomer Strong evidence[5][6].
Tacrolimus — A documented case showed CBD roughly tripled tacrolimus trough levels at high doses. Tacrolimus has a narrow therapeutic window; levels above the target range increase infection and toxicity risk Strong evidence[7].
Valproate — Co-administration with CBD increases the risk of elevated liver enzymes (ALT and AST). The mechanism is not purely pharmacokinetic — valproate itself can raise liver enzymes, and CBD may compound this — but the interaction is clinically meaningful Strong evidence[3][4].
Other antiepileptic drugs — Topiramate, rufinamide, zonisamide, and eslicarbazepine levels have all been shown to rise with CBD co-administration in epilepsy trials Strong evidence[8].
These interactions are referenced in the FDA's Epidiolex (cannabidiol) prescribing information [3]. They are not folklore or anecdotes.
What might work (plausible but limited data)
These interactions are biologically plausible because the drugs are metabolized by CYP enzymes that CBD inhibits. But human data are thin — often limited to case reports, in vitro studies, or pharmacokinetic modeling.
Statins — Simvastatin and atorvastatin are heavily CYP3A4-dependent and carry the classic grapefruit warning. CBD plausibly raises their levels and could increase the risk of muscle toxicity (statin-related myopathy). However, human data are limited to in vitro studies and pharmacokinetic modeling; no controlled trials in real patients exist Weak / limited[2][9].
SSRIs and other serotonin or norepinephrine reuptake inhibitors — Sertraline, citalopram, escitalopram, and others metabolized by CYP2C19 or CYP3A4 could see modest level increases. A handful of case reports exist. Clinically relevant in some patients, probably not in most Weak / limited.
Benzodiazepines (diazepam, alprazolam, midazolam) — These are CYP3A4 substrates. Interaction is biologically plausible; controlled data in humans on CBD are thin Weak / limited.
Direct oral anticoagulants (DOACs: apixaban, rivaroxaban) — Apixaban and rivaroxaban are CYP3A4 and P-glycoprotein substrates. Case reports of bleeding exist; controlled studies do not Weak / limited[10].
What doesn't work or lacks evidence
The claim that topical CBD interacts with oral medications — overwhelmingly unlikely. Systemic absorption from topical CBD products is very low; levels in blood after topical application are often undetectable or negligible Weak / limited.
The idea that "full-spectrum" CBD avoids interactions because of the entourage effect — there is no evidence for this. Full-spectrum products still contain CBD, often at the same doses as isolate, and still inhibit CYP enzymes No data.
The claim that very low doses (5–10 mg/day) cause clinically meaningful interactions — possible but not well documented. Most interaction data come from doses above 100 mg/day or from epilepsy trials at 10–20 mg/kg/day. Low-dose users on a single non-critical medication are probably at low risk, but the dose-response curve is not well mapped Weak / limited.
The argument that "CBD is natural so it's safe" — natural does not mean inert. Grapefruit is also natural. Many plant alkaloids are potent enzyme inhibitors.
What we don't know
- The dose-response curve below ~10 mg/kg/day is poorly mapped. Most rigorous data come from Epidiolex trials at 10–20 mg/kg/day. Whether interactions occur at lower doses is largely unstudied.
- Whether inhaled or vaped CBD produces a different interaction profile than oral CBD. Inhaled CBD bypasses first-pass liver metabolism; the duration and magnitude of enzyme inhibition may differ, but no controlled studies exist.
- How CBD interacts with most of the top 100 prescribed drugs in the U.S. We have systematic data for perhaps a few dozen; the rest are inference from enzyme inhibition data or case reports.
- Whether genetic CYP variants (poor metabolizers vs. extensive metabolizers) change the interaction magnitude meaningfully. This is plausible but unstudied in CBD users.
- The clinical significance of CBD's effects on UGT enzymes, which handle drugs like lamotrigine, morphine, and bilirubin. These are less well characterized than CYP inhibition.
Comparison with standard practice
Pharmacists already have tools to screen for CYP3A4 and CYP2C interactions. The infrastructure to handle CBD exists — clinicians just need to know to enter it into their drug-interaction checker.
Many electronic health record (EHR) systems now flag CBD as a potential interactor; not all do. If your EHR does not include CBD, mention it when you talk to your pharmacist.
For patients seeking a reference:
- The FDA's Epidiolex prescribing information [3] lists the most clinically important interactions.
- The Indiana University Flockhart Table on CYP-mediated interactions [11] is free and regularly updated.
- Many hospital and pharmacy school websites publish a "grapefruit list" that can be used as a first-pass filter.
Compared to grapefruit, CBD's enzyme inhibition is generally:
- Longer-lasting — grapefruit's effect wears off over 24–72 hours; CBD with daily dosing produces sustained inhibition.
- Broader — CBD hits more enzymes than just CYP3A4 (it also inhibits CYP2C9, CYP2C19, and others).
- Dose-controllable — you choose your CBD dose; grapefruit serving sizes and furanocoumarin content vary widely.
Risks and practical guidance
Risk categories:
- High risk — narrow-therapeutic-index drugs: warfarin, tacrolimus, cyclosporine, clobazam, certain chemotherapeutics, immunosuppressants. Do not add CBD without your prescriber knowing. If you do add it, drug-level monitoring is essential.
- Moderate risk — statins, SSRIs, antipsychotics, opioids metabolized by CYP3A4 (fentanyl, oxycodone), DOACs. A conversation with your pharmacist is worth it. Symptoms of overdose (muscle pain for statins, serotonin syndrome for SSRIs, bleeding for anticoagulants) warrant urgent attention.
- Low risk — drugs not metabolized by CYP450 enzymes or UGT: lithium, gabapentin, metformin, levothyroxine. Interaction is unlikely, though always mention CBD to your clinician.
If you take prescription medication and are considering CBD:
- Check whether your medication has a grapefruit warning on the label or in the package insert. If yes, categorize it as at least moderate risk.
- Ask your pharmacist — they are usually the most accessible interaction expert and may already have CBD in their system.
- If you and your clinician decide CBD is worth it, start at a low dose, increase gradually, and consider checking drug levels (INR for warfarin, trough levels for tacrolimus, liver enzymes for valproate) after starting and after any CBD dose change.
- Tell every clinician you see that you use CBD. They cannot screen for what they don't know about.
- Watch for signs of drug toxicity — increased bleeding (warfarin), muscle pain (statins), tremor or sedation (antiepileptics) — and report them immediately.
Do not stop a prescribed medication based on this article. If you are concerned, discuss the risk with your pharmacist or doctor, and let them make the decision.
This is not medical advice
This article summarizes published evidence for general education. Drug interactions depend on your specific medications, doses, liver function, genetics, age, and other factors. Talk to a pharmacist or physician before combining CBD with prescription drugs. Do not stop, start, or change a prescribed medication based on anything you read here.
Sources
- Peer-reviewed Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine. 2019;8(7):989.
- Peer-reviewed Bansal S, Maharao N, Paine MF, Unadkat JD. Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. Drug Metabolism and Disposition. 2020;48(10):1008–1017.
- Government U.S. Food and Drug Administration. Epidiolex (cannabidiol) oral solution — Prescribing Information. 2018; revised 2020.
- Peer-reviewed Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246–1251.
- Peer-reviewed Grayson L, Vines B, Nichol K, Szaflarski JP. An interaction between warfarin and cannabidiol, a case report. Epilepsy & Behavior Case Reports. 2017;9:10–11.
- Peer-reviewed Damkier P, Lassen D, Christensen MMH, Madsen KG, Hellfritzsch M, Pottegård A. Interaction between warfarin and cannabis. Basic & Clinical Pharmacology & Toxicology. 2019;124(1):28–31.
- Peer-reviewed Leino AD, Emoto C, Fukuda T, et al. Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. American Journal of Transplantation. 2019;19(10):2944–2948.
- Peer-reviewed Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58(9):1586–1592.
- Peer-reviewed Balachandran P, Elsohly M, Hill KP. Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review. Journal of General Internal Medicine. 2021;36(7):2074–2084.
- Peer-reviewed Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes involved in the metabolism of cannabidiol by human liver microsomes. Life Sciences. 2011;89(5–6):165–170.
- Practitioner Flockhart DA, Thacker D, McDonald C, Desta Z. The Flockhart Cytochrome P450 Drug-Drug Interaction Table. Division of Clinical Pharmacology, Indiana University School of Medicine. 2021.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- CBD and Methotrexate — A real interaction exists, but human evidence for benefit is absent.